

Key Information Document

Purpose

This information sheet provides you with key information about this investment product. It is not marketing material. This information is required by law to help you understand the type of product, the risks and costs involved as well as the potential profits and losses, and to help you compare it with other products.

Product

Product name	Multi Manager Access II - Future of Humans, a sub-fund of Multi Manager Access II, class USD F-acc
Manufacturer	UBS Fund Management (Luxembourg) S.A.
ISIN	LU2213664688
Telephone number	Call +352 27 1511 for more information.
Website	www.ubs.com/funds

The Commission de Surveillance du Secteur Financier (CSSF) is responsible for supervising UBS Fund Management (Luxembourg) S.A in relation to this Key Information Document.

This PRIIP is authorized in Luxembourg.

The Management Company is authorised in Luxembourg and supervised by the Commission de Surveillance du Secteur Financier (CSSF).

Date of production of the KID: 17 July 2024.

What is this product?

Type

Multi Manager Access II is an undertaking for collective investment in transferable securities (UCITS) incorporated in the legal form of an investment company with variable capital (SICAV) under Part I of the Luxembourg 2010 Law on undertakings for collective investment.

Term

The Product does not have a maturity date (the Product has been established for an indefinite period of time). The Manufacturer may terminate the Product early. The amount you will receive upon early termination may be less than the amount you invested.

The recommended holding period (RHP) is displayed in the section "How long should I hold it and can I take money out early?".

Objectives

The objective of the actively managed sub-fund is to seek long-term real returns by pursuing a thematic strategy which relate to the trends towards an ageing population, the global growth in population and increasing urbanisation. These aspects can comprise any sectors, countries and company capitalisations in order to benefit from disruptive developments in society, resources and technology, with a focus on longevity, education, healthcare and consumer preferences.

The sub-fund is a multi-manager portfolio utilizing leading institutional asset managers with proven expertise in the relevant thematic area.

The sub-fund is actively managed and as such does not seek to replicate or track any benchmark index. The sub-fund follows a thematic approach with each theme referencing one of the following Reference Benchmark Indices to whose components a minimum of 40% of the equity investments for that theme will be allocated: MSCI ACWI IMI Genomics Innovation Index, MSCI ACWI IMI Ageing Society Opportunities Index, MSCI ACWI IMI Future Education Index, MSCI ACWI IMI Millennial Consumer Select Index.

The Portfolio Managers may also employ derivatives in achieving the investment objective of the sub-fund.

The investment policy allows significant flexibility on the extent to which the single stock allocation, sector and country exposure of the sub-fund may deviate from the Reference Benchmark Indices, meaning the portfolio composition of the sub-fund may deviate materially from the Reference Benchmark Indices. Therefore, the performance of the sub-fund may materially diverge from the performance of the Reference Benchmark Indices.

The sub-fund uses the MSCI ACWI Net Total Return index for performance comparison purposes only.

The sub-fund may enter into securities lending transactions.

Sustainability risks are not systematically integrated on the basis of the investment strategy and the type of underlying investments.

The return of the fund depends primarily on equity market development and their exchange rate fluctuations, as well as dividend payments.

The income in respect of an accumulation share class is not distributed but is retained in the sub-fund.

Intended retail investor

This fund applies to retail investors with a basic financial understanding, who can accept a possible loss on the investment amount. The fund is aimed at growing the investment value, while granting daily access to the capital under normal market conditions. With their investment in this fund, investors can satisfy medium term investment needs. The fund is only suited to be acquired within a discretionary mandate.

Depository

UBS Europe SE, Luxembourg Branch

Further Information

Information about Future of Humans and the available share classes, the full prospectus, and the latest annual and semi-annual reports, as well as additional information can be obtained free of charge from the fund management company, the central administrator, the custodian bank, the fund distributors or online at www.ubs.com/funds. Latest price can be found at www.ubs.com/funds

What are the risks and what could I get in return?

Indicator



Lower risk

Higher risk



The risk indicator assumes you keep the product for 5 years.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 4 out of 7, which is a medium risk class.

This rates the potential losses from future performance at a medium level. The past may be a poor predictor of the future and, hence, the actual risk of losing money may vary significantly.

The product may be exposed to further risk factors such as operational, political and legal risks which are not included in the summary indicator. Please refer to the prospectus for more detail.

This product does not include any protection from future market performance so you could lose some or all of your investment. If we are not able to pay you what is owed, you could lose your entire investment.

Performance Scenarios

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate and favourable scenarios shown are illustrations using the worst, average, and best performances of the product over the last 10 years. Markets could develop very differently in the future.

Recommended holding period:		5 years	
Example Investment:		USD 10 000	
		If you exit after 1 year	If you exit after 5 years
Scenarios			
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.		
Stress	What you might get back after costs	USD 1 450	USD 1 560
	Average return each year	-85.5%	-31.0%
Unfavourable	What you might get back after costs	USD 6 670	USD 7 810
	Average return each year	-33.3%	-4.8%
Moderate	What you might get back after costs	USD 10 230	USD 13 030
	Average return each year	2.3%	5.4%
Favourable	What you might get back after costs	USD 13 860	USD 18 500
	Average return each year	38.6%	13.1%

The stress scenario shows what you might get back in extreme market circumstances.

The figures shown include all costs of the product itself. The figures do not take account of your personal tax situation, which can also have an impact on how much you receive back.

Unfavourable scenario: This type of scenario occurred for an investment between 2021 and 2024.

Moderate scenario: This type of scenario occurred for an investment between 2014 and 2019.

Favourable scenario: This type of scenario occurred for an investment between 2016 and 2021.

What happens if UBS Fund Management (Luxembourg) S.A. is unable to pay out?

Losses are not covered by an investor compensation or guarantee scheme. Furthermore, with respect to UBS Europe SE, Luxembourg Branch as depositary of the Fund, which is responsible for the safekeeping of the assets of the Fund (the "Depositary"), there is a potential default risk if the assets of the Fund held with the Depositary are lost. However, such default risk is limited as the Depositary is required by law and regulation to segregate its own assets from the assets of the Fund. The Depositary is liable to the Fund or to the investors of the Fund for the loss by the Depositary or one of its delegates of a financial instrument held in custody unless the Depositary is able to prove that the loss has arisen as a result of an external event beyond its reasonable control.

What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Costs over time

The table shows the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods, we have assumed that the product performs as shown in the moderate scenario.
- 10 000 USD is invested.

	If you exit after 1 year	If you exit after 5 years
Total costs	USD 390	USD 827
Annual cost impact (*)	3.9%	1.6% each year

(*) This illustrates how costs reduce your return each year over the holding period. For example, it shows that if you exit at the recommended holding period your average return per year is projected to be 7.9% before costs and 6.4% after costs.

Composition of costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	3.0% of the amount you pay in when entering this investment. This is the most you will be charged. The person selling you the product will inform you of the actual charge.	Up to USD 300
Exit costs	We do not charge an exit fee for this product, but the person selling you the product may do so.	USD 0
Ongoing costs taken each year		
Management fees and other administrative or operating costs	0.9% of the value of your investment per year. This is an estimate based on actual costs over the last year.	USD 86
Transaction costs	0.1% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	USD 11
Incidental costs taken under specific conditions		
Performance fees	There is no performance fee for this product.	USD 0

he figures shown here do not include any additional fees that may be charged by your distributor, advisor or any insurance wrapper in which the fund may be placed. For additional information about costs, refer to the prospectus, which is available at www.ubs.com/funds

How long should I hold it and can I take money out early?

Recommended holding period: 5 Year(s)

The recommended holding period for this product is 5 year(s). This is our recommended holding period based on the risk and expected return with the product. Please note that the expected return is not guaranteed. The more the actual holding period deviates from the recommended holding period for the product, the more your actual return will also deviate from the product assumptions. Depending on your needs and limitations, a different holding period may be suitable for you. Consequently, we recommend that you discuss this issue with your customer service representative.

Investors may demand to redeem their units on every normal bank business day in Luxembourg.

How can I complain?

If you have a complaint about the product, the manufacturer of the product or the person who recommended or sold the product to you, please speak to your client advisor or contact us at www.ubs.com/fml-policies

Other relevant information

Information on past performance and previous performance scenario calculations can be found at www.ubs.com/funds

Swiss representative: UBS Fund Management (Switzerland) AG, Aeschenvorstadt 1, CH-4051 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich and its branches in Switzerland. To obtain documents: The prospectus, key investor information and articles of association, as well as the annual and semi-annual reports (if available), can be obtained free of charge from the representative and at www.ubs.com/funds